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Abstract Preventing breast cancer is an effective strategy
for reducing breast cancer deaths. The purpose of chemo-
prevention (also termed preventive therapy) is to reduce
cancer incidence by use of natural, synthetic, or biological
agents. The efficacy of tamoxifen, raloxifene, and
exemestane as preventive therapy against estrogen-receptor
(ER)-positive breast cancer is well established for women at
increased risk for breast cancer. However, because breast
cancer is a heterogeneous disease, distinct preventive ap-
proaches may be required for effective prevention of each
subtype. Current research is, therefore, focused on identify-
ing alternative mechanisms by which biologically active
compounds can reduce the risk of all breast cancer subtypes
including ER-negative breast cancer. Promising agents are
currently being developed for prevention of HER2-positive
and triple-negative breast cancer (TNBC) and include inhib-
itors of the ErbB family receptors, COX-2 inhibitors, met-
formin, retinoids, statins, poly(ADP-ribose) polymerase in-
hibitors, and natural compounds. This review focuses on
recent progress in research to develop more effective pre-
ventive agents, in particular for prevention of ER-negative
breast cancer.
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Introduction
Given the global increase in cancer incidence with its associ-
ated morbidity, mortality, and enormous treatment costs, there
is increasing interest in strategies for disease prevention. Breast
cancer is the most common form of cancer among women
worldwide, with an estimated 232,340 new cases among US
women in 2013 alone [1]. In the US the incidence has been
stable over the last decade, although increasing almost every-
where throughout the world. Although breast cancer mortality
is declining [1, 2], preventing breast cancer is the most effec-
tive way of reducing breast cancer death. Primary prevention
focuses on preventing cancer from developing or delaying the
development of a malignancy. Prevention strategies encom-
pass avoidance of known carcinogens (e.g. benzene), promo-
tion of behavioral strategies to reduce risk through diet, exer-
cise, limited alcohol consumption, and no tobacco use. For
individuals with a particularly high risk of breast cancer, man-
agement includes genetic screening, early detection by use of
mammography and breastMRI, use of preventivemedications,
and such surgical strategies as bilateral mastectomy.
Prevention of either the initial phases of carcinogenesis or
the progression of premalignant cells to invasive disease,
thereby reducing the risk of cancer, can be achieved by phar-
macological means, commonly referred to as chemopreven-
tion (also termed preventive therapy). The purpose of chemo-
prevention is to reduce cancer incidence by use of natural,
synthetic, or biological agents. The value of this approach has
been demonstrated in breast cancer prevention trials which
have primarily focused on endocrine intervention by use of
selective estrogen receptor modulators (SERMs; for example
tamoxifen) and aromatase inhibitors (AIs; for example
exemestane) (comprehensively reviewed elsewhere [3]).
Because breast cancer includes both estrogen-receptor-
positive (ER-positive) and estrogen-receptor-negative (ER-
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negative) subtypes, distinct chemopreventive approaches may
be required for effective prevention of each subtype.
Promising approaches to prevention of ER-negative breast
cancer include targeting molecules critical for the growth
and progression of ER-negative tumors, for example inhibi-
tors of the ErbB family of receptors, cyclooxygenase-2 (COX-
2) inhibitors, metformin, retinoids, statins, poly(ADP-ribose)
polymerase, natural compounds, and others (Fig. 1).
Studies leading to successful FDA approval of anti-
estrogenic drugs for prevention of ER-positive breast cancer
among high-risk women are reviewed briefly below.
However, these drugs do not reduce the risk of ER-negative
breast cancer, which accounts for 20–30 % of breast cancers.
Therefore, we also review chemopreventive approaches to
reducing the risk of ER-negative breast cancer.
Subtypes of Breast Cancer
The classical breast cancer subtypes are based on assess-
ment of clinical and pathological factors, for example ER,
progesterone receptor (PR), or HER2 status, tumor grade,
tumor size, and the presence or absence of lymph node
metastasis. However, microarray-based gene-expression
studies have led to the identification of molecular subtypes
(basal-like, HER2-enriched, luminal, and normal breast-
like) with distinctly different survival and treatment re-
sponse [4, 5]. Luminal tumors are ER and PR-positive
whereas HER2-positive tumors arise from overexpression
or amplification of the EGFR family of receptor tyrosine
kinases, particularly HER2 (also called ErbB2, neu). HER2
overexpression is present in approximately 20–30 % of all
human breast tumors, particularly those that are ER-
negative [6]. Triple-negative breast cancer (TNBC) is char-
acterized by lack of expression of ER, PR, and HER2 and
accounts for approximately 15–20 % of all breast cancer
diagnoses. TNBC is molecularly a heterogeneous disease.
Most basal-like breast cancers (∼80 %) are of the triple-
negative phenotype. More recently, TNBC has been divided
into six distinct subtypes:
1. immunomodulatory;
2. mesenchymal;
3. mesenchymal stem-like;
4. luminal androgen receptor;
5. basal-like 1; and
6. basal-like 2 [7].
Fig. 1 Molecular targets for
breast cancer chemoprevention.
Solid lines indicate drugs
currently used in preclinical or
clinical chemopreventive studies
whereas dotted lines indicate
promising drugs for future
chemopreventive studies.
mTORC1, mammalian target of
rapamycin complex 1 composed
of mTOR, Raptor, MLST8,
PRAS40, and DEPTOR [121];
mTORC2, mammalian target of
rapamycin complex 2 composed
of mTOR, RICTOR, mLST8 and
mSIN1 [122].
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Therefore, the development of effective preventive agents
suppressing the development of TNBC remains a challenge,
because of the heterogeneity of the disease.
Prevention of ER-Positive Breast Cancers
ER and its ligand estrogen are key regulators in breast cancer
carcinogenesis, and modulation of the receptor or reduction of
estrogen are strategies for reduction of breast cancer risk.
Clinical studies testing SERMs, for example tamoxifen, or
AIs, for example anastrozole, for treatment of early breast
cancer laid the foundation for breast cancer prevention in the
future.
The National Surgical Adjuvant Breast and Bowel Project
(NSABP) BCPT (also known as P-1) trial demonstrated that
tamoxifen reduced the risk of invasive breast cancer by 49 %
versus placebo among women at risk [8]. The STAR trial
demonstrated that raloxifene was as effective as tamoxifen,
and reduced breast cancer risk in postmenopausal women by
approximately 50 % [9]. The results of the P-1 and STAR
trials led to FDA approval of tamoxifen or raloxifene for use
for breast cancer prevention among high-risk women. More
recently, the 81-month follow-up study demonstrated that
after stopping drug treatments after five years the cancer-
preventive effect of tamoxifen persisted whereas the cancer-
preventive effect of raloxifene diminished over time.
Raloxifene retained only 76 % of the effectiveness of tamox-
ifen at prevention of invasive breast cancer [10]. However,
raloxifene was generally less toxic than tamoxifen, which is
of particular interest for high-risk postmenopausal women
with intact uterus who are concerned about the risk of hot
flushes, thromboembolic side effects, and endometrial cancer,
whereas tamoxifen may be preferred for a high-risk postmen-
opausal woman without a uterus, and for premenopausal
women [11].
Clinical trials of AIs as adjuvant therapy demonstrated their
cancer-preventive potential, because they effectively prevent
breast cancer recurrence [12, 13] and the development of
second primary contralateral tumors [12]. The NCIC-MAP.3
trial tested the aromatase inhibitor exemestane versus placebo
among postmenopausal high risk women for up to five years
of treatment [14]. In this trial, exemestane reduced the inci-
dence of invasive breast cancer by 65 % and the incidence of
ER-positive invasive breast cancer by 73 %. Adverse events,
for example endometrial cancers and thromboembolic events,
which are usually associated with tamoxifen treatment, were
not reported. On the other hand, exemestane is associated with
hot flushes and bone pain, and increases the risk of bone
fracture [14]. The IBIS-II trial tested the cancer-preventive
effect of another AI, anastrozole, among postmenopausal
women at risk for breast cancer. The results of this trial, in
which women were treated with 1 mg oral anastrozole or
placebo every day for five years, were recently reported
[15]. Anastrozole reduced the incidence of breast cancer by
53 % among high-risk postmenopausal women [15].
Although AIs are not yet FDA-approved for breast cancer
prevention, these drugs are already being used off-label for
this purpose. The success of SERMS and AIs demonstrates
that preventive therapy for breast cancer is possible.
Prevention of HER2-Positive Breast Cancer
Several different ErbB family receptor inhibitors are FDA-
approved for clinical use. The monoclonal antibodies
cetuximab, trastuzumab, and pertuzumab are directed against
the extracellular domain of their target receptor proteins and
prevent receptor interaction with growth factor and/or dimer-
ization with other receptors whereas the small-molecule in-
hibitors lapatinib, gefitinib, and erlotinib interfere with the
kinase activity of their target proteins (Fig. 1) [16]. Given
the activity of these drugs in cancer treatment research is
now focused on investigating in particular oral HER2 and
EGFR receptor tyrosine kinase inhibitors in preclinical and
early clinical trials as breast cancer-preventive drugs.
In preclinical mouse models our group has shown that
treatment with gefitinib, an EGFR kinase inhibitor, delayed
the development of spontaneous ER-negative, HER2-positive
mammary tumors in the MMTV-ErbB2 transgenic mouse
model [17] (median time to tumor formation in the control
group 230 days versus 310 days in the high-dose gefitinib
group, p<0.001) (Table 1). Furthermore, gefitinib reduces
proliferation and tumor multiplicity (Table 1) [18, 19].
Likewise, Lapatinib, a dual EGFR and ErbB2 receptor tyro-
sine kinases inhibitor, or vehicle was administered long-term
to MMTV-ErbB2 transgenic mice before the development of
tumors. Lapatinib inhibited the formation of premalignant
lesions in the mammary gland and reduced ER-negative and
HER2-positive tumor development by 69 % (Table 1) [20].
Lapatinib was further investigated in clinical trials. In a
phase II trial lapatinib (1,500 mg once a day) or placebo was
investigated for treatment of 60 women with HER2-positive
ductal carcinoma in situ (DCIS) for three weeks before surgi-
cal resection [21]. Primary endpoint results revealed reduced
proliferation of breast epithelial cells, adjacent ductal
intraepithelial neoplasia, and distant ductal hyperplasia (indi-
cated by immunohistochemical staining for KI67) (Table 2)
[21]. Another similar trial among women with HER2 or
EGFR-positive DCIS is currently testing the effect of lapatinib
(1000 mg day−1) versus placebo for two to six weeks before
surgical excision. The primary objective is to determine the
rate of proliferation of DCIS breast cancer cells measured by
immunohistochemical staining for Ki67. Secondary endpoints
include investigation of whether lapatinib affects the inci-
dence of DCIS observed at time of surgical excision (Table 2).
Treatment of HER2-positive DCIS with trastuzumab, a
monoclonal antibody against HER2, was tested in a phase II
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trial in a neoadjuvant setting. Preoperative single-dose mono-
therapy with trastuzumab resulted in an immunologic re-
sponse (increased antibody-dependent cell-mediated cytotox-
icity) with no association in histologic, antiproliferative, or
apoptotic changes (Table 2) [22]. In an ongoing phase III
NSABP-43 trial the effect of trastuzumab is being assessed
in women with HER2-positive DCIS after excisional surgery
given concurrently with radiation or radiation alone. The
primary objective is to determine whether trastuzumab pre-
vents subsequent recurrence of ipsilateral breast cancer, ipsi-
lateral skin cancer, or ipsilateral DCIS. One of the secondary
objectives is to determine whether trastuzumab has a preven-
tive effect in prolonging invasive or DCIS disease-free sur-
vival (Table 2).
In addition to FDA-approved HER2/EGFR inhibitors, such
alternative approaches as use of Her-2/neu vaccines to manip-
ulate the immune system with long-lasting anti-tumor effects
are under investigation. Several systems have been developed
to deliver tumor-associated antigens into the body, for exam-
ple whole tumor cell vaccines, dendritic cell vaccines, viral
vector vaccines, and peptide vaccines, the last being the focus
of clinical investigations among high-risk women for preven-
tion of HER2-positive breast cancer. The most studied HER2-
derived peptide in clinical trials is E75 (NeuVax, HER2/neu
369–377), an immunogenic HLA class-I peptide that stimu-
lates cytotoxic T lymphocytes. Results from phase II studies
suggest that E75, in particular when administered in the adju-
vant setting, prevents disease recurrence among selected high-
risk patients [23, 24]. The first phase III clinical trial, called the
PRESENT trial, will determine the efficacy and safety of E75
vaccine and evaluate and compare disease-free survival (DFS)
among E75 vaccinated patients and control patients. Another
ongoing phase II study will investigate the combination of
immunotherapy with E75 and trastuzumab to prevent recur-
rence among high-risk HER2-positive breast cancer patients
who are disease-free after standard of care therapy.
Preventive Agents for ER-Negative Breast Cancer
Including TNBC
NSAIDs, Aspirin, and COX-2 Inhibitors
Increasing epidemiological, experimental, and clinical studies
have demonstrated that nonsteroidal anti-inflammatory drugs
(NSAIDs) have a preventive effect on the development of
some malignancies including breast cancer. NSAIDs inhibit
cyclooxygenase (COX), for which two isoforms, COX-1 and
COX-2, have been described. COX-1 is constitutively pro-
duced in most cells whereas COX-2 is induced by mitotic
signals and pro-inflammatory stimuli [25]. NSAIDs impair the
transformation of arachidonic acid to prostaglandins (Fig. 1),
prostacyclin, and thromboxanes. COX-2 is overexpressed inTa
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invasive breast cancer, and in DCIS and adjacent tissue,
suggesting COX-2 is an important driver of mammary tumor-
igenesis [26].
Most traditional NSAIDs, for example aspirin, are nonse-
lective inhibitors of both COX-1 and COX-2. Randomized
studies have identified reduced cancer risk (e.g., lung, colon,
breast) associated with long-term use of aspirin [27]. A meta-
analysis showed that long-term aspirin intake is associated
with a 10 % reduction in risk of breast cancer [28].
Extended follow-up revealed overall cancer mortality was
reduced by approximately 20 % among people with regular
intake of aspirin, with the greatest benefit seen in deaths from
adenocarcinoma (36 % reduction) [27].
The selective COX-2 inhibitors celecoxib (Celebrex),
rofecoxib (Vioxx), and valdecoxib (Bextra) have received ap-
proval from the FDA in the US for treatment of pain; rofecoxib
and valdecoxib were, however, withdrawn worldwide by the
manufacturer after an increased number of cardiovascular events
was seen in placebo-controlled trials. Therefore, subsequent
research has focused on investigating the cancer-preventive
effectiveness of celecoxib in preclinical and clinical studies.
In preclinical studies treatment with celecoxib reduced
mammary tumor incidence among treated mice [29, 30].
However, one study using the same mouse model showed
that celecoxib was unable to prevent tumor development [31].
Our group showed celecoxib alone was ineffective but coad-
ministration of celecoxib and bexarotene, a rexinoid, substan-
tially delayed tumor development (Table 1) [32].
Recently, a phase II biomarker trial has demonstrated that
celecoxib reduced proliferation in primary breast cancer tis-
sues [33]. The first phase III clinical trial, called REACT,
assessing the disease-free survival benefit of two years of
celecoxib treatment among women with resected primary
breast cancer is currently in progress (Table 2).
Although COX inhibitors have a significant chemopreven-
tive effect on breast cancer risk, further clinical trials are
needed. Moreover, concerns about rare serious toxicity, car-
diovascular toxicity associated with COX-2 inhibitors, and
other known potential side effects of treatment with
NSAIDS, for example gastrointestinal bleeding and perfora-
tion, should be taken into account before routine implemen-
tation of NSAIDS as chemoprevention for breast cancer. To
advance this field, new less toxic drugs targeting the COX2
pathway will need to be developed.
Metformin
Metformin (1,1-dimethylbiguanide) is the most widely used
first-line therapy of choice for type 2 diabetes mellitus. The
primary target of metformin is AMPK in the mitochondria
[34, 35]. Upon disruption of mitochondrial complex I, AMP/
ATP and ADP/ATP ratios are increased which activates
AMPK [34, 35] (Fig. 1). AMPK activation controls many
metabolic processes, including fatty acid synthesis, gluconeo-
genesis in the liver, and glucose uptake in muscle (reviewed
elsewhere [36]). However, the molecular mechanism of the
preventive effect of metformin is still not understood. It is
suggested that reduced insulin levels on treatment with met-
formin result in reduction of cell growth, thereby reducing
tumorigenesis [37].
Epidemiological studies recently confirmed an association
between type 2 diabetes and breast cancer risk, predominantly
among postmenopausal women [38]. Moreover, other retro-
spective studies have demonstrated that metformin, in partic-
ular, reduces the risk of breast cancer compared with other
antidiabetic therapy (e.g., insulin, alpha-glucosidase inhibi-
tors, prandial glucose regulators, sulfonylureas,
thiazolidinediones) [39–44]. In laboratory studies, metformin
inhibits mammary tumor growth (Table 1) [45] and selectively
targets tumor-initiating cells in this mouse model [46].
Because of these promising epidemiologic and preclinical
data, several phase I and II trials were conducted to investigate
its breast cancer-preventive effects [47–49]. Most of these
studies were neoadjuvant “window of opportunity” studies
among women with operable breast cancer and investigated
a variety of biomarker changes after metformin administration
(Table 2). Metformin reduced proliferation (KI67) and in-
creased apoptosis (TUNEL staining) in invasive tumor tissue
[49, 50]. Phase II and III clinical trials are currently in progress
to further elucidate the cancer-preventive effect of metformin
[51–55]. One important currently ongoing phase III study is
the NCIC-MA.32 trial testing five years of metformin or
placebo among women with early-stage breast cancer [51].
The primary outcome is invasive disease-free survival, with
overall survival and contralateral breast cancer incidence as
secondary endpoints (Table 2).
The results of these clinical trials will determine whether
metformin will be useful for the prevention of breast cancer.
Retinoids
Evidence from in-vitro studies suggest that retinoids control
various signaling mechanisms irrespective of the ER/PR sta-
tus of the cell, whichmakes them particularly promising drugs
for prevention of ER-negative breast cancer. Retinoids are
vitamin A analogues that regulate gene expression by binding
to nuclear hormone receptors, including retinoic acid recep-
tors (RARs) and retinoid X receptors (RXRs) [56]. Retinoids,
for example all-trans-retinoic acid (ATRA), alitretinoin (9-cis-
RA), and isotretinoin (13-cis-RA), can activate RAR and
RXR, which heterodimerize and bind to the DNA on RA
response elements to induce activation of genes involved in
cellular proliferation, differentiation, and apoptosis [56].
Retinoids have been successfully used for prevention and
treatment of cancers [57] and a variety of preclinical studies
using mouse and rat models have demonstrated reduced
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mammary tumorigenesis because of the cancer-preventive
effect of retinoids [58–60]. Preclinical studies also elucidated
specific retinoid-mediated mechanisms of the cancer-
preventive effect; these include:
& down-regulation of expression of COX2 and cyclin D1 [61];
& inhibition of AP1 transcription factor activity [62, 63];
& induction of cell cycle arrest at G1 [64, 65]; and
& overexpression of IGF binding proteins (IGF-BPs) 3 and 6
[63], RAR-beta [63] and TGF-beta [66].
One of the first chemoprevention trials among humans
showed that 13-cis-RA prevented second primary tumors
among head and neck patients [67]; for chemoprevention,
however, the toxicity associated with 13-cis-RA treatment is
not acceptable. Similarly, toxicity associated with 9-cis-RA
treatment prevented further development of this agent as a
standard chemopreventive drug [60, 67].
The synthetic retinoic acid, fenretinide, has been widely
studied in clinical trials of chemoprevention, because of its
favorable toxicity profile compared with the previously men-
tioned retinoids. In a phase III trial women with breast cancer
were randomly assigned to receive no treatment or oral
fenretinide (200 mg) daily for five years [68]. After a median
follow-up of eight years, fenretinide treatment did not reduce
the incidence of second breast cancers overall; when given to
premenopausal women, however, fenretinide resulted in sig-
nificant (38 %) reduction of the risk of second breast cancers
(Table 2) [68, 69].
Rexinoids
Synthetic “rexinoids” (e.g. bexarotene and LG100268) activate
RXR without activating RAR nuclear receptors [70–73].
Bexarotene is FDA-approved for the treatment of cutaneous T-
cell lymphoma; it has been tested for treatment of advanced
breast cancer but was not effective as a single agent [74]. Our
laboratory has previously shown that bexarotene can prevent
ER-negative/HER2 positive mammary tumors in preclinical
mouse models (Table 1) [73]. A breast cancer prevention trial
of bexarotene among women at genetic risk showed that it
reduced proliferationmarkers (Ki67, CyclinD1) in breast tissues
[75]. However, as with 13-cis-RA and 9-cis-RA, bexarotene had
significant side effects, for example hypertriglyceridemia, which
was reversible upon stopping the drug [75].
9cUAB30 is a synthetic analog of 9-cis-RAwith little or no
RAR-binding activity compared with 9-cis- RA and other
retinoids [76]. Preclinical animal studies proved the chemo-
preventive activity of 9cUAB30 in reduction of mammary
cancers (Table 1) [76, 77]. A first study among humans
recently demonstrated a favorable toxicity and pharmacoki-
netic profile of 9cUAB30, and a phase I dose-escalation study
is currently in progress.
Our laboratory has previously shown that the rexinoid
LG100268 can prevent ER-negative/HER2 positive mamma-
ry tumors in preclinical mouse models [78] and delay TNBC
development [79]. Moreover, combination therapy using
LG100268 and a synthetic triterpenoid, CDDO-methyl amide,
synergistically suppressed ER-negative/HER2 positive mam-
mary tumors (Table 1) [70]. Future preclinical and clinical
studies are needed to determine the future of retinoids and
rexinoids as cancer-preventive agents. Other approaches, for
example combination treatments may be a promising new
strategy to reduce ER-negative breast cancer incidence.
Statins
Statins inhibit 3-hydroxy-3-methyl-glutaryl-coenzyme A
(HMG-CoA) reductase, which reduces the intracellular bio-
synthesis of cholesterol by reversibly inhibiting the conver-
sion of HMG-CoA to mevalonate (Fig. 1) [80]. These lipid-
lowering drugs (for example atorvastatin, cerivastatin,
fluvastatin, lovastatin, simvastatin, and pravastatin) are com-
monly used to treat hypercholesterolemia, and thereby reduce
the risk of cardiovascular diseases. Preclinical, clinical, and
epidemiologic studies provide a rationale for evaluating lipo-
philic statins for breast cancer prevention [80–83]. Results
from these studies are conflicting, however, resulting in in-
consistency in the relationship between statin use and reduced
incidence of breast cancer.
A decrease in risk of many types of cancer, including breast
cancer, among statin users was observed in many studies [81,
84–88]. Conversely, twometa-analyses concluded that statin use
and long-term statin use did not significantly affect breast cancer
risk [89, 90]. A recently conducted study revealed no association
of lipid-lowering drug use with reduced risk of breast cancer
recurrence and breast cancer-specific mortality [91].
To investigate the biological effect of lipophilic statins in
the prevention of breast cancer several biomarker modulation
trials have been initiated [92, 93]. After short-term statin
treatment of women with high-grade (DCIS or stage 1) breast
cancer, proliferation was reduced and apoptosis increased
(Table 2) [93]. However, another biomarker modulation trial
of lovastatin among women with increased risk of breast
cancer did not show any significant breast duct cytology
changes after lovastatin therapy [94].
In the future, it will be necessary to conduct clinical trials
among high-risk populations, in particular women at high risk
of TNBC, to determine whether statins will be useful as
preventive therapy.
PARP Inhibitors
Poly(ADP-ribose) polymerases, particularly PARP1, are mul-
tifunctional enzymes best known for their repair of breaks in
single-strand DNA. Inhibition of PARP-1 is a promising
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approach for targeted prevention of breast cancer, especially
among women with deleterious BRCAmutations [95]. Several
PARP inhibitors, for example iniparib (BSI-201), olaparib
(AZD2281), rucaparib (AG014699), veliparib (ABT-888),
and BMN-673, are currently in clinical development as cancer
therapeutics for breast and ovarian cancer [95]. However, lim-
ited data exists on studies testing the efficacy of PARP inhib-
itors as a prevention agent. A recent preclinical study by Liby
and Sporn demonstrated that olaparib (200 mg kg−1 diet) or
veliparib (100 mg kg−1 diet) significantly delayed tumor devel-
opment in BRCA1-deficient mice (Table 1) [96]. PARP inhib-
itors have not yet been tested for chemoprevention in clinical or
biomarkermodulation trials. However, PARP inhibitors may be
found to be useful for cancer prevention in the future, consid-
ering approximately 55 to 65 % of BRCA1 mutation carriers
will develop breast cancer by age 70 years [97].
Other Promising Agents
Novel targeted drugs with demonstrated efficacy for treatment
of breast cancer may also be useful for prevention of breast
cancer. IGF-pathway inhibitors, for example cixutumumab or
figitumumab, have been effective in the treatment of both ER-
positive and ER-negative breast cancer [98]. However, little
progress has been made in determining the usefulness of these
drugs as preventive therapy, partly because of their known
toxicity, for example hyperglycemia. PI3K/AKT/mTOR sig-
naling is critical for regulation of cell growth and cell survival
and is thus important in tumorigenesis [99]. mTOR, a serine-
threonine kinase, acts as a downstream effector of the
PI3K/AKT signaling pathway and phosphorylates multiple
downstream kinases [100]. mTOR inhibitors (for example
rapamycin, everolimus, sirolimus, and temsirolimus) may be
useful as cancer-prevention agents. Rapamycin has been used
in several preclinical studies (Table 1) which demonstrated
that this drug is able to reduce tumor growth in ER-negative
breast tumor mouse models [101, 102]. These initial positive
results are encouraging for further development of mTOR
inhibitors as cancer preventive agents.
A variety of triterpenoids have chemopreventive potential
in breast cancer. Natural triterpenoids are abundantly found in
marine sources, for example marine sponges, sea cucumbers,
or marine algae [103], and have antiproliferative,
antiangiogenic, anti-inflammatory, and pro-apoptotic activity
[104]. CDDO esters and CDDO-Me have been shown to
delay ER-negative mammary tumor formation in animal stud-
ies (Table 1) [70, 105].
Natural Compounds
Although there is a strong interest in using more than one-
hundred natural compounds [106] for cancer prevention, none
of these dietary agents has been shown to consistently prevent
breast cancer. Some of the most promising compounds include
catechins (e.g., epigallocatechin gallate (EGCG), green tea
extract) [107], curcumin [108], luteolin [109], carotenoids
[110], omega-3-fatty acids [111], resveratrol [112–114], soy
isoflavones [115, 116], and vitamin D [117, 118]. For exam-
ple, green tea intake has been associated with reduced inci-
dence of breast cancer, and a recent phase IB dose-escalation
trial using 400–800 mg EGCG among women with a history
of stage I to III hormone receptor-negative breast cancer
demonstrated that this natural compound is well tolerated
[107] (Table 2). On the basis of this positive result, a phase
II trial testing the cancer-preventive effect of EGCG over a one
year treatment period is currently in progress among postmen-
opausal women with high breast density. Many vitamins, in
particular Vitamin D, are currently being tested as preventive
agents among women at high risk of breast cancer. The
VITAL trial (vitamin D and omega-3 fatty acids) is testing
the daily intake of vitamin D3 (2000 IU), omega-3 fatty acids
(1000mg), the combination, or placebo among 20,000 healthy
men and women for five years [119] (Table 2). The primary
outcomes are cancer incidence, cardiovascular disease, stroke,
and diabetes. Although natural products are a promising alter-
native cancer-prevention strategy, their potential efficacy in
the prevention of ER-negative and, particularly, triple-
negative breast cancer will be determined in the near future.
How to Select Individuals for Preventive Therapy (Risk
Stratification)
Accurate assessment of a women’s breast cancer risk on the
basis of known risk factors is needed to decide who might
benefit most from targeted preventive therapy. In particular,
targeted chemoprevention will be used for women at high risk.
For example, womenwith HER2-positive DCIS would benefit
from anti-HER2 therapy after consideration of risk versus
benefit factors. To this end, statistical models have been de-
veloped to help predict breast cancer risk on the basis of
known risk factors. Themost frequently used is the Gail model
(reviewed elsewhere [120]), although this model is not able to
specify a risk for solely ER-positive or solely ER-negative
breast cancer. Each of the currently available risk-prediction
models has its limitations and cannot be appropriately applied
to all patients. Incorporation of known biomarkers, gene-
expression profiles and pharmacogenetics, susceptibility
genes, and breast density is needed to accurately identify
women at particularly high risk of ER-negative breast cancer.
Conclusions and Future Perspective
Because breast cancer comprises distinct subtypes, identifica-
tion and development of effective and safe preventive therapy
remains challenging. To successfully implement preventive
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therapy for all types of breast cancer, chemoprevention must
change to personalized therapy. For example, several preven-
tion trials among women with HER2-positive DCIS have dem-
onstrated the potential of HER2-targeted drugs as chemopre-
ventive agents for this subtype of breast cancer. The heteroge-
neous nature of TNBCs, which have multiple signaling path-
ways activated, necessitates multi-targeted approaches to effec-
tive TNBC prevention. Moreover, successful cancer prevention
requires accurate identification of individuals at high risk of
specific breast cancer subtypes. Such high-risk individuals are
most likely to benefit from targeted preventive therapy.
Although many women qualify for preventive therapy, most
high-risk women are not interested in using drugs for cancer
prevention. This is partly because of the perception that the
benefits do not outweigh the side effects. Whereas many wom-
en with cancer will tolerate side effects during their therapy,
most women do not accept the same side effects of preventive
therapywhen healthy. To overcome this challenge, education of
the public and medical community with evidence-based risk
and benefit information is needed. Moreover, most preventive
therapy is administered chronically for many years; other strat-
egies, for example intermittent dosing schedules should be
investigated to reduce common and rare serious side effects.
The success of breast cancer prevention research depends
on molecularly targeted approaches, particularly for TNCB
prevention, and the development of less toxic drugs that
interrupt drivers of tumorigenesis.
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